Patients who received olopatadine/mometasone either once or twice daily experienced significant improvements in their instantaneous Total Nasal Symptom Scores compared with placebo.
GSP301 treatment was associated with a significant improvement in reflective and instantaneous Total Nasal Symptom Scores compared with placebo.
Patients who received a fixed-dose combination nasal spray showed significantly improved Physician-assessed Nasal Symptom Scores compared with those who received placebo.
The majority of study participants had rhinitis at baseline, including perennial allergic rhinitis with seasonal exacerbations, which is the most severe phenotype.
Childhood non-atopic rhinitis is associated with an increased risk for adult asthma.
Fluticasone Propionate Nasal Spray is a corticosteroid indicated for the management of the nasal symptoms of perennial nonallergic rhinitis in adults and pediatric patients aged 4 years and older.
Only 16.5% of pharmacy customers with hay fever select optimal medications.
Patients with chronic rhinosinusitis may experience decreases in health-related quality of life comparable to other serious chronic diseases.
Intranasal corticosteroids are the current guideline-preferred treatment recommendation for nasal congestion.
Children who are exposed to antibiotics earlier in life may have an increased risk for allergic diseases, including asthma, atopic dermatitis, and allergic rhinitis.
Over 10 years, patients with local allergic rhinitis show worsening of rhinitis, development of asthma, and poor quality of life.
Allergic and nonallergic rhinitis guidelines include the latest updates from BSACI for diagnosing and managing children and adults.
A study of 65 patients examined the efficacy of using serum periostin as a biomarker for asthma with comorbid upper airway disease.
Smokers had worse rhinosinusitis symptoms and used more antibiotics and oral corticosteroids to treat sinus infections.
Sublingual immunotherapy is associated with slower AR progression and less frequent asthma onset in patients with allergic rhinitis.
Two years is insufficient for sublingual immunotherapy to induce long-term clinical efficacy in allergic rhinitis.
Researchers examined the impact of uncontrolled allergic rhinitis on work productivity.